New Zealand markets close in 3 hours 21 minutes

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4500-0.2100 (-12.65%)
At close: 04:00PM EDT
1.4400 -0.01 (-0.69%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 237.40M
Enterprise value 768.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.41
Price/book (mrq)N/A
Enterprise value/revenue 5.30
Enterprise value/EBITDA -3.53

Trading information

Stock price history

Beta (5Y monthly) 0.43
52-week change 3-66.26%
S&P500 52-week change 3-6.69%
52-week high 35.0600
52-week low 30.5800
50-day moving average 31.5424
200-day moving average 32.2193

Share statistics

Avg vol (3-month) 313.06M
Avg vol (10-day) 33.11M
Shares outstanding 5143.88M
Implied shares outstanding 6N/A
Float 8141.82M
% held by insiders 11.44%
% held by institutions 139.91%
Shares short (14 Jul 2022) 428.58M
Short ratio (14 Jul 2022) 41.08
Short % of float (14 Jul 2022) 420.25%
Short % of shares outstanding (14 Jul 2022) 419.86%
Shares short (prior month 14 Jun 2022) 441.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -178.28%
Operating margin (ttm)-146.49%

Management effectiveness

Return on assets (ttm)-26.53%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)144.95M
Revenue per share (ttm)1.17
Quarterly revenue growth (yoy)-10.00%
Gross profit (ttm)115.3M
EBITDA -204.16M
Net income avi to common (ttm)-258.42M
Diluted EPS (ttm)-2.0840
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)122.24M
Total cash per share (mrq)0.85
Total debt (mrq)653.56M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.52
Book value per share (mrq)-2.11

Cash flow statement

Operating cash flow (ttm)-192.66M
Levered free cash flow (ttm)-119.77M